Einstein Image: Lynch Syndrome
Einstein Image: Lynch Syndrome
Image courtesy of Kyeryoung Lee, Ph.D., a research associate in Dr. Edelmann’s lab
Lynch syndrome is an inherited condition that greatly increases the risk for intestinal cancer. In this image, the drug rapamycin has eliminated differentiated tumor cells from the small intestine of a Lynch syndrome mouse model, but two types of cancer stem cells have resisted rapamycin: Lgr5+ (green) and Bmil+ (purple) stem cells. (Also visible are Lgr5+ stem cell–associated Paneth cells, in red.)
Tumors return when rapamycin therapy is stopped—and Lgr5+ cells, in particular, are suspected of regenerating tumors. Winfried Edelmann, Ph.D., and colleagues are studying a drug that makes Lgr5+ cells sensitive to rapamycin by inhibiting the membrane protein MDR1 (multi-drug resistance 1), which pumps out rapamycin and other anticancer drugs. Dr. Edelmann is a professor of cell biology and of genetics and the Joseph and Gertrud Buchler Chair in Transgenic Medicine at Einstein.
The Issue at a Glance
Highlights
- The Search for Autism Therapies
- Collaborating to Cure Cancers
- No Insurance? No Problem for ECHO Clinic
- An Out-of-This-World NASA Clerkship
Features
Campus News
- Dr. Cuervo Elected to National Academy of Sciences
- Dr. Cabana Named New Chair of Pediatrics
- Drs. Berman and Cunningham Give Presidential Lecture
- Tenure for 16 Einstein Professors
- Dr. Sanjay Gupta of CNN Speaks at Einstein’s Commencement
- Forbes Ranks Einstein Among Nation’s Best Midsize Employers
- Einstein M.D./Ph.D. Student Wins Lasker Essay Contest
- Dr. Benfield Named First Diversity and Inclusion Chief
